09:00 – 10:40
SESSION 7: Immunotherapy
| Chairs | Dr. Ana Alarcón Tomás Hospital Universitario Puerta de Hierro, Madrid, Spain Dr. Margarida Coucelo Unidade Local de Saúde de Coimbra, Portugal Dr. Alessandro Isidori Marche Nord Hospital, Pesaro, Italy |
| 09:00 - 09:20 | Immunopeptidome Analysis in AML Dr. Joaquín Sánchez Hospital Universitario Reina Sofía, Córdoba, Spain |
| 09:20 - 09:40 | CAR-T Therapy Beyond CD19 Dr. Felipe Prósper Clínica Universidad de Navarra, Pamplona, Spain |
| 09:40 - 10:00 | A Novel Macrophage Activator, Bexmarilimab, Results on AML and MDS Dr. Mika Kontro Helsinki University Hospital Comprehensive Cancer Center, Finland |
| 10:00 - 10:20 | Bi-Specific Antibodies for AML Dr. Ana Alfonso Pierola Clínica Universidad de Navarra, Pamplona, Spain |
| 10:20 - 10:40 | Discussion |
10:40 – 11:00
Coffee break
11:00 – 12:20
SESSION 8: Fit and Unfit in AML: A Matter Beyond Age
| Chairs | Dr. Gabriela Rodríguez Macías Hospital General Universitario Gregorio Marañón, Madrid, Spain Dr. Anne Louise Tølbøll Sørensen Copenhagen University Hospital - Rigshospitalet, Denmark Dr. Carlos Plaza UEES Clinic y SOLCA Guayaquil, Ecuador |
| 11:00 - 11:20 | Multidisciplinary Management, the Role of the Geriatrician Dr. Maite Vidán Hospital General Universitario Gregorio Marañón, Madrid, Spain |
| 11:20 - 11:40 | Intensive Strategies in High-Risk AML: Beyond 7+3 Dr. Alessandro Isidori Ospedale Marche Nord, Pesaro, Italy |
| 11:40 - 12:00 | How to Treat Patients Aged 80 and Above Dr. Yakir Moshe Tel Aviv Sourasky Medical Center, Israel |
| 12:00 - 12:20 | Discussion |
12:20 – 13:20
SESSION 9: BPDCN
| Chairs | Dr. Mayte Olave Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain Dr. Mar Tormo Hospital Clínico Universitario de Valencia, Spain Dr. María Marta Rivas Hospital Universitario Austral, Buenos Aires, Argentina |
| 12:20 - 12:40 | BPDCN Diagnostic and Therapeutic Challenge Dr. María Belén Vidriales Hospital Clínico Universitario de Salamanca, Spain |
| 12:40 - 13:00 | BPDCN Management and Real-Life Data Dr. Claudio Cerchione IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST, Meldola, Italy |
| 13:00 - 13:20 | Discussion |
13:20 – 14:25
SESSION 10: Re-Thinking AML management
| Chairs | Dr. David Valcárcel Hospital Universitario Vall d'Hebron, Institute of Oncology, Barcelona, Spain Dr. Adolfo de la Fuente MD Anderson Cancer Center Madrid-Hospiten, Spain Dr. Guillermo García-Manero MD Anderson Cancer Center, Houston, USA Dr. Claudio Cerchione IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST, Meldola, Italy |
| 13:20 - 13:40 | Low-Intensity Treatment in AML, Focusing on Monotherapy vs. Combinations vs. Sequencing Dr. Gail Roboz New York Presbyterian Hospital, USA |
| 13:40 - 14:00 | Rethinking the Role of Intensive Chemotherapy for Fit Patients Dr. Alexander Perl Abramson Cancer Center, Pennsylvania, USA |
| 14:00 - 14:25 | Discussion |
14:25 – 15:30
Lunch
15:30 – 16:10
SESSION 11: Meet the Expert Management of FLT3 Mut AML in 1st Line
| Chairs | Dr. María Marta Rivas Hospital Universitario Austral, Buenos Aires, Argentina Dr. Claudia Núñez-Torrón Stock Hospital Universitario Infanta Sofía, Madrid, Spain Dr. Adolfo de la Fuente MD Anderson Cancer Center Madrid-Hospiten, Spain |
| 15:30 - 15:50 | FLT3 Inhibitors in Frontline, the Big Picture Dr. Luís Pedro Monteiro Unidade Local de Saúde São José, Lisboa, Portugal |
| 15:50 - 16:10 | Experts Dr. Alexander Perl Abramson Cancer Center, Pennsylvania, USA Dr. Hartmut Döhner Universitätsklinikum Ulm, Germany |
16:10 – 17:30
SESSION 12: My Day-to-Day Life at the AML
| Chairs | Dr. Mónica Alejandra Romero Riquelme Hospital Clínico Regional Dr. Guillermo Grant Benavente, Concepción, Chile Dr. Guillermo García-Manero MD Anderson Cancer Center, Houston, USA Dr. Gilberto Barranco Hospital General de México, Mexico |
| 16:10 - 16:30 | Maintenance in AML to Whom and with What Between Opportunities and Restrictions Dr. Anne Louise Tølbøll Sørensen Copenhagen University Hospital - Rigshospitalet, Denmark |
| 16:30 - 16:50 | Treatment of NPM1 Mutated AML Dr. Mar Tormo Hospital Clínico Universitario de Valencia, Spain |
| 16:50 - 17:10 | Advances in Relapsed AML Dr. Josefina Serrano Hospital Universitario Reina Sofía, Córdoba, Spain |
| 17:10 - 17:30 | Discussion |
17:30-18:50
SESSION 13: Targeted Therapies
| Chairs | Dr. Gabriela Rodríguez Macías Hospital General Universitario Gregorio Marañón, Madrid, Spain Dr. Mika Kontro Helsinki University Hospital Comprehensive Cancer Center, Finland Dr. Mónica Alejandra Romero Riquelme Hospital Clínico Regional Dr. Guillermo Grant Benavente, Concepción, Chile |
| 17:30 - 17:50 | Menin Inhibitors in AML Dr. Cristina Papayannidis IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy |
| 17:50 - 18:10 | Targeting KIT in Systemic Mastocytosis Dr. Iván Álvarez-Twose Complejo Hospitalario Universitario de Toledo, Spain |
| 18:10 - 18:30 | Targeting KMT2A in ALL Dr. Elias Jabbour MD Anderson Cancer Center, Houston, USA |
| 18:30 - 18:50 | Discussion |